- Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
- Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
- Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
- Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
- Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
- CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
- Organovo to Participate in the H.C. Wainwright Global Investment Conference
- Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
More ▼
Key statistics
On Thursday, Organovo Holdings Inc (ONVO:NAQ) closed at 0.991, 16.59% above the 52 week low of 0.85 set on May 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.03 |
---|---|
High | 1.04 |
Low | 0.99 |
Bid | 0.981 |
Offer | 1.03 |
Previous close | 0.991 |
Average volume | 132.11k |
---|---|
Shares outstanding | 12.99m |
Free float | 12.80m |
P/E (TTM) | -- |
Market cap | 12.87m USD |
EPS (TTM) | -2.17 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼